Get the Stockscreener App
12.18
0.83%
0.10
Intellia Therapeutics Inc stock is traded at $12.18, with a volume of 3.42M.
It is up +0.83% in the last 24 hours and down -7.16% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.08
Open:
$11.94
24h Volume:
3.42M
Relative Volume:
1.38
Market Cap:
$1.24B
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-2.2308
EPS:
-5.46
Net Cash Flow:
$-382.65M
1W Performance:
-5.58%
1M Performance:
-7.16%
6M Performance:
-49.57%
1Y Performance:
-58.88%
1-Day Range:
$11.85
$12.45
1-Week Range:
$11.79
$13.79
52-Week Range:
$11.79
$34.87
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.18 | 1.24B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Cathie Wood's ARK buys Intellia, sells Tesla in latest stock trades - Investing.com
Intellia Crashes 60% in a Year: How Should You Play the Stock? - Nasdaq
First Week of February 2025 Options Trading For Intellia Therapeutics (NTLA) - Nasdaq
Barclays PLC Buys 44,022 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month LowHere's What Happened - MarketBeat
3 Things You Need to Know if You Buy CRISPR Therapeutics Today - AOL
State Street Corp Raises Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
(NTLA) Proactive Strategies - Stock Traders Daily
Intellia Therapeutics' SWOT analysis: gene editing stock faces pivotal year - Investing.com
Intellia Therapeutics' SWOT analysis: gene editing stock faces pivotal year By Investing.com - Investing.com UK
Short Interest in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Rises By 15.5% - MarketBeat
Wellington Management Group LLP Has $13.25 Million Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 4.2%Here's What Happened - MarketBeat
Intellia stock touches 52-week low at $12.81 amid biotech slump - Investing.com
The Right Fit: What BMS, Intellia Look for in Cell and Gene Therapy Talent - BioSpace
Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Intellia Not Entitled to 'Safe Harbor' in BlueAllele Patent Suit - Bloomberg Law
Intellia Can't Escape Patent Suit Over $100M Regeneron Deal - Law360
Two Sigma Advisers LP Buys 257,700 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 52,297 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Fmr LLC - MarketBeat
Charles Schwab Investment Management Inc. Acquires 37,714 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.5%Time to Buy? - MarketBeat
Benjamin Edwards Inc. Has $1.19 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Verition Fund Management LLC Purchases 50,763 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
(NTLA) Investment Analysis - Stock Traders Daily
Shareholders in Intellia Therapeutics (NASDAQ:NTLA) have lost 88%, as stock drops 4.7% this past week - Simply Wall St
Future-Proofing Growth of Gene Editing Technology Innovation - openPR
Patient Square Capital LP Invests $2.64 Million in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Chevy Chase Trust Holdings LLC Sells 231,592 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
PDT Partners LLC Reduces Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
BNP Paribas Financial Markets Has $5.06 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Awards Key Executive Inducement Grant with 3-Year Vesting Schedule | NTLA Stock News - StockTitan
CRISPR Technology Market Growth Trends from 2024 to 2033 | Key - openPR
Intellia Therapeutics Announces Promising CRISPR Therapy Results - TipRanks
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy - MSN
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? - Benzinga
Intellia Therapeutics' SWOT analysis: gene editing firm's stock faces pivotal trials - Investing.com
Gene-editing therapy aiding FAP patients year or more later: Trial - FAP News Today
Hereditary Angioedema Market Expected to Experience Major - openPR
Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks - 2 Minute Medicine
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - The Manila Times
Intellia's CRISPR Therapy Nex-Z Secures FDA RMAT Designation for Rare Disease Treatment | NTLA Stock News - StockTitan
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? - sharewise
Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online
Equities Analysts Offer Predictions for NTLA FY2025 Earnings - MarketBeat
Intellia Therapeutics price target lowered to $55 from $76 at Barclays - MSN
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates - MSN
This Beaten-Down Stock Could Soar by 354%, According to Wall Street - AOL
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):